CytoSorbents to Report Third Quarter 2026 Financial Results
CytoSorbents Corporation announced it will release its financial results for the third quarter of 2026 after the market closes on November 12, 2026.
Stocks · News reference
WBB Securities Initiates Coverage on CytoSorbents with Speculative Buy Rating and $9.50 Price Target
WBB Securities has initiated coverage on CytoSorbents Corporation with a 'Speculative Buy' rating and a price target of $9.50 per share.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — Cytosorbents Corp (CTSO)
Filed: 2026-09-23 AccNo: 0001104659-26-109814 Size: 286 KB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
CytoSorbents Regains Nasdaq Compliance
CytoSorbents Corporation (NASDAQ:CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces that it has regained compliance with
Cytosorbents Announces 1-for-20 Reverse Stock Split, Effective September 8
Reverse Stock Split Previously Approved by Shareholders; Intended to Support Compliance with Nasdaq's $1.00 Minimum Bid Price RequirementExpected to Become Effective and Trade on Split-Adjusted Basis at the Market
CytoSorbents Says Real-World Matched Analysis Of 587 Urgent CABG Patients On Ticagrelor Showed 37% Relative Reduction In Severe Bleeding With CytoSorb; Plans New DrugSorb-ATR De Novo Submission In Early 2027
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Dermata Therapeutics (NASDAQ:DRMA) stock moved upwards by 44.4% to $1.56 during Tuesday's after-market session. The company's market cap stands at $4.5 million. As per the news, the Q2 earnings report